Michael Grissinger - 28 Jun 2024 Form 4 Insider Report for Akari Therapeutics Plc (AKTX)

Role
Director
Signature
/s/ Wendy F. DiCicco, as Attorney-in-Fact for Michael Grissinger
Issuer symbol
AKTX
Transactions as of
28 Jun 2024
Transactions value $
$0
Form type
4
Filing time
02 Jul 2024, 16:30:11 UTC
Previous filing
21 Jun 2024
Next filing
21 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKTX Stock Option (Right to Buy) Award $0 +5,000,000 $0 5,000,000 28 Jun 2024 Ordinary Shares, par value $0.0001 per share 5,000,000 $0.0014 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock options have an exercise price of $0.001395 per ordinary share, par value $0.0001 per share ("Ordinary Share").
F2 Non-qualified stock option granted under the Issuer's 2023 Equity Incentive Plan. One-hundred percent (100%) of the stock option vests and becomes exercisable on the date of the Issuer's 2025 Annual General Meeting of Shareholders, subject to continued service with the Issuer.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents 2,000 Ordinary Shares.

Remarks:

See Exhibit 24.1 - Power of Attorney